Sex Differences in Levodopa‐Sparing Effect of Safinamide: Post‐hoc Findings from a Multicenter, Longitudinal, Case‐Control Study

Key Points

The research aims to explore the impact of sex on the levodopa-sparing effects of safinamide in Parkinson's Disease management.
Conducted a multicenter, longitudinal, case-control design
Examined the effects of safinamide 100 mg on levodopa use in both sexes
Analyzed data to compare the response between men and women
Safinamide exhibited a larger levodopa-sparing effect in women than in men
Support for sex-specific approaches in dopaminergic therapy
Highlights the need for tailored treatment strategies based on gender

Post-hoc analysis reveals greater levodopa-sparing effects of safinamide in women with Parkinson's disease, suggesting targeted therapy adjustments.

Safinamide 100 mg provides a larger levodopa-sparing effect in women, supporting sex-specific optimization of dopaminergic therapy in PD management.

No takes yet. Share an insight, caveat, or question.

Cilia et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share